ArticleAlzheimer's & dementia (New York, N. Y.)2022

Impact of non-binding FDA guidances on primary endpoint selection in Alzheimer's disease trials.

Jeffrey C Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.